Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BYFrontiers in microbiomes

Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.

  1. 1Digbi Health, Mountain View, CA, United States.

Abstract

Gastrointestinal (GI) adverse events, such as nausea, vomiting, diarrhea, and constipation, remain a dominant barrier to the sustained use of GLP-1 receptor agonists (GLP-1 RAs), driving discontinuation independently of the drug's metabolic benefits. Two host-side biological systems have been independently established as determinants of this variability. The first is host genetics, anchored by a 2026 genome-wide association study in which GLP1R variants predicted both weight-loss efficacy and nausea or vomiting risk, while a GIPR signal for vomiting was restricted to tirzepatide users. The second system is the gut microbiome, which regulates endogenous GLP-1 secretion through short-chain fatty acid and bile acid signaling and is itself reshaped by GLP-1 RA exposure. Pharmacomicrobiomics integrates host genetic and microbiome data to explain drug response. In the literature surveyed for this review, these two determinants are consistently examined in parallel rather than jointly: we did not identify a study, in GLP-1 RA therapy or in another drug class, that fit a 'host-genotype-by-microbiome' interaction model against a drug tolerability outcome. Published methodological studies have suggested why such a study would be challenging: both interaction detection and the measurement unreliability associated with single-timepoint microbiome profiling impose substantial sample size penalties. This review summarizes what host genetics and the microbiome individually do and do not explain about GLP-1 RA tolerability, and describes the study design features, paired genotyping, repeat-sample metagenomics, and prospective symptom capture that a future joint analysis would require.

Related

  1. Microbial dysbiosis and treatment-related gastrointestinal adverse events in locoregionally advanced nasopharyngeal carcinoma: an exploratory study of the oral and gut microbiome
    Yi Chen, Caixiu Huang, Yating Qin +5
    BMC CancerPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
  2. Microbiome-driven precision psychiatry: integrating multi-omics, artificial intelligence, and personalized interventions along the gut-brain axis
    Yi Zhang, Changyong Pei, Daohua Zhang +1
    Frontiers in medicinePeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
  3. Integrating multi-omics technologies to decipher microbiome functions
    Tim van den Bossche, Eunice Adeline Lazau, Velma Aho +42
    Nature CommunicationsPeer-reviewedCC BYFull text1 citedMolecular biology & gene regulationHAL
  4. High efficacy and tolerability of daratumumab-based regimens in first-line treatment of patients with immunoglobulin light-chain amyloidosis: a real-world evidence analysis
    Yajuan Cui, Yunya Luo, Ji Li +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCEurope PMCPMC
  5. Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
    Xin-yu Li, Zuo-quan Xie, Mei-yu Geng
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text1 citedMolecular biology & gene regulationPMC
BibTeX
@article{kumbhare2026pharmacomicrobiomics,
  title = {{Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.}},
  author = {Shreyas V Kumbhare and Inti Pedroso and Ranjan Sinha and Daniel E Almonacid},
  journal = {Frontiers in microbiomes},
  year = {2026},
  month = oct,
  doi = {10.3389/frmbi.2026.2016564},
  url = {https://europepmc.org/article/MED/43011784},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.
AU  - Shreyas V Kumbhare
AU  - Inti Pedroso
AU  - Ranjan Sinha
AU  - Daniel E Almonacid
PY  - 2026
DA  - 2026/10/27
JO  - Frontiers in microbiomes
DO  - 10.3389/frmbi.2026.2016564
UR  - https://europepmc.org/article/MED/43011784
AB  - Gastrointestinal (GI) adverse events, such as nausea, vomiting, diarrhea, and constipation, remain a dominant barrier to the sustained use of GLP-1 receptor agonists (GLP-1 RAs), driving discontinuation independently of the drug's metabolic benefits. Two host-side biological systems have been independently established as determinants of this variability. The first is host genetics, anchored by a 2026 genome-wide association study in which GLP1R variants predicted both weight-loss efficacy and nausea or vomiting risk, while a GIPR signal for vomiting was restricted to tirzepatide users. The second system is the gut microbiome, which regulates endogenous GLP-1 secretion through short-chain fatty acid and bile acid signaling and is itself reshaped by GLP-1 RA exposure. Pharmacomicrobiomics integrates host genetic and microbiome data to explain drug response. In the literature surveyed for this review, these two determinants are consistently examined in parallel rather than jointly: we did not identify a study, in GLP-1 RA therapy or in another drug class, that fit a 'host-genotype-by-microbiome' interaction model against a drug tolerability outcome. Published methodological studies have suggested why such a study would be challenging: both interaction detection and the measurement unreliability associated with single-timepoint microbiome profiling impose substantial sample size penalties. This review summarizes what host genetics and the microbiome individually do and do not explain about GLP-1 RA tolerability, and describes the study design features, paired genotyping, repeat-sample metagenomics, and prospective symptom capture that a future joint analysis would require.
SN  - 2813-4338
ER  -